Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 2492423-29-5 Chemical Structure| 2492423-29-5

Structure of Molnupiravir
CAS No.: 2492423-29-5

Chemical Structure| 2492423-29-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Molnupiravir is an orally bioavailable form of a highly potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Molnupiravir

CAS No. :2492423-29-5
Formula : C13H19N3O7
M.W : 329.31
SMILES Code : O[C@H]1[C@@](O[C@H](COC(C(C)C)=O)[C@H]1O)(N2C(=O)N/C(=N\O)/C=C2)[H]
MDL No. :MFCD32663515
InChI Key :HTNPEHXGEKVIHG-QCNRFFRDSA-N
Pubchem ID :145996610

Safety of Molnupiravir

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H315-H319-H228
Precautionary Statements:P240-P210-P241-P264-P280-P302+P352-P370+P378-P337+P313-P305+P351+P338-P362+P364-P332+P313
Class:4.1
UN#:1325
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
A549-hACE2 cells 2.8 μM 48 hours Evaluate the inhibitory effect of Molnupiravir on SARS-CoV-2 nLUC replication, showing dose-dependent antiviral effects Sci Transl Med. 2022 May 4;14(643):eabm3410
Calu-3 cells 10 μM 48 hours To validate the antiviral activity of Molnupiravir against SARS-CoV-2 in Calu-3 cells, results showed significant antiviral effects. Nature. 2022 Apr;604(7904):134-140
human airway organoids (hAOs) 10 μM Validate the antiviral activity of Molnupiravir in hAOs. Results showed that 10 μM Molnupiravir reduced viral RNA levels by >90%. Cell Res. 2022 Mar;32(3):322-324
human lung epithelial Calu-3 cells 1 μM, 10 μM 48 hours Evaluate the antiviral activity of Molnupiravir against the Omicron variant. Results showed that 1 μM Molnupiravir reduced viral RNA by 70.4%, and complete inhibition was achieved at 10 μM and higher concentrations. Cell Res. 2022 Mar;32(3):322-324

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Syrian Gold hamsters SARS-CoV-2 infection model Oral 250 mg/kg Twice daily for 6 days Evaluate the inhibitory effect of drug combination on SARS-CoV-2 replication, results showed combination treatment significantly reduced viral load iScience. 2022 May 20;25(5):104293.
Ferrets Upper respiratory infection model Oral 5 mg/kg Twice daily for 4 days Assess the therapeutic effect of EIDD-1931 on upper respiratory infection, showing significant reduction in viral shedding and prevention of transmission. Nat Commun. 2022 Jul 29;13(1):4416.
Sprague-Dawley rats Pregnant rat model Intravenous injection 100 mg/kg Single dose To investigate the pharmacokinetics and placental transfer of EIDD-1931 in pregnant rats. Results showed that EIDD-1931 rapidly crosses the placental barrier into the fetus, and its concentration in the fetus was higher than the IC50 for SARS-CoV-2. EBioMedicine. 2023 Sep;95:104748
C57BL/6 mice SARS-CoV infection model Oral 50, 150, 500 mg/kg Every 12 hours until the end of the study Evaluate prophylactic and therapeutic efficacy of EIDD-2801 against SARS-CoV, significantly reduced weight loss and lung hemorrhage, decreased virus titer Sci Transl Med. 2020 Apr 29;12(541):eabb5883
Ferrets SARS-CoV-2 infection model Oral gavage 5 mg/kg or 15 mg/kg Twice daily, continued until four days after infection To evaluate the therapeutic effect of oral MK-4482/EIDD-2801 on SARS-CoV-2 infection in ferrets, results showed significant reduction in upper respiratory tract viral load and complete suppression of virus transmission to untreated contact animals. Nat Microbiol. 2021 Jan;6(1):11-18
Ferrets Upper respiratory infection model Oral 5 mg/kg Every 12 hours for 4 days Assess the therapeutic effect of Molnupiravir on upper respiratory infection, showing significant reduction in viral shedding and prevention of transmission. Nat Commun. 2022 Jul 29;13(1):4416
Syrian hamsters SARS-CoV-2 infection model Oral gavage 250 mg/kg Dosed every 12 hours for 3 days To assess the inhibitory effect of MK-4482 on SARS-CoV-2 replication, results showed that MK-4482 significantly reduced viral lung loads and pathology Nat Commun. 2021 Apr 16;12(1):2295
BALB/C mice SARS-CoV-2 Beta variant infection model Oral 50 mg/kg and 150 mg/kg Twice daily for 2 days To evaluate the antiviral efficacy of Molnupiravir in a mouse model of SARS-CoV-2 Beta variant infection, results showed significant reduction in viral titers and lung inflammation. Nature. 2022 Apr;604(7904):134-140
Balb/c mice HCoV-OC43 infection model Oral 200 mpk Once daily for 4 days Evaluate the therapeutic efficacy of Molnupiravir against HCoV-OC43 infection, showing significant reduction in viral load. Signal Transduct Target Ther. 2023 Sep 22;8(1):360

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06615869 Healthy PHASE1 COMPLETED 2023-03-15 QPS-MRA, LLC-Early Phase (Site... More >> 0002), South Miami, Florida, 33143, United States Less <<
NCT05386758 Renal Impairment PHASE1 COMPLETED 2023-03-01 Velocity Clinical Research, Ha... More >>llandale Beach ( Site 0005), Hallandale Beach, Florida, 33009, United States|Advanced Pharma CR, LLC ( Site 0004), Miami, Florida, 33147, United States|Genesis Clinical Research, LLC ( Site 0003), Tampa, Florida, 33603, United States|Thomas Jefferson University-Pharmacology, Physiology and Cancer Biology ( Site 0001), Philadelphia, Pennsylvania, 19107, United States Less <<
NCT05386589 Hepatic Impairment PHASE1 COMPLETED 2023-01-05 Research Centers of America ( ... More >>Hollywood ) ( Site 0002), Hollywood, Florida, 33024, United States|Clinical Pharmacology of Miami ( Site 0003), Miami, Florida, 33014, United States|Thomas Jefferson University - Pharmacology and Experimental Therapeutics ( Site 0001), Philadelphia, Pennsylvania, 19107, United States Less <<
NCT05412173 Viral Infection|COVID-19 COMPLETED 2022-06-02 Limited Liability Company "Res... More >>earch Center Eco-Safety", Saint Petersburg, 196143, Russian Federation Less <<
NCT06223932 COVID-19|SARS-CoV-2 Infection ACTIVE_NOT_RECRUITING 2025-02-24 Istanbul University, Istanbul ... More >>Faculty of Medicine, Department of Infectious Disease, Istanbul, Fatih, 34093, Turkey|Cerrahpasa Faculty of Medicine Infectious Disease Departament, Istanbul, Fatih, Turkey|Ankara City Hospital, Ankara, Turkey|Ankara University Faculty of Medicine, Ankara, Turkey|CAM and SAKURA Training and Research Hospital, Istanbul, Turkey|Istanbul Haseki Training and Research Hospital, Istanbul, Turkey|Koc University Hospital, Istanbul, Turkey|Umraniye Training and Research Hospital, Istanbul, Turkey Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.04mL

0.61mL

0.30mL

15.18mL

3.04mL

1.52mL

30.37mL

6.07mL

3.04mL

References

 

Historical Records

Categories